Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11.5B | $2.7B | $3.4B | $0.8B | 23.3% | 29.3% |
| 2025-12-31 | $12.5B | $1.1B | $2.8B | $1.6B | 8.7% | 22.5% |
| 2025-09-30 | $12.2B | $2.2B | $3.6B | $6.0B | 18.0% | 29.8% |
| 2025-06-30 | $12.3B | $1.3B | $3.8B | $3.6B | 10.7% | 30.8% |
| 2025-03-31 | $11.2B | $2.5B | $3.5B | $1.7B | 21.9% | 31.2% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
| 2024-09-30 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-04-30 | 1.31 | 1.15 | +13.9% |
| 2026-02-05 | 0.53 | 0.98 | -45.7% |
| 2025-10-30 | 1.08 | 1.04 | +3.4% |
| 2025-07-31 | 0.64 | 0.67 | -3.8% |
| 2025-04-24 | 1.80 | 1.50 | +19.9% |
| 2025-02-06 | 0.04 | 0.90 | -95.6% |
| 2024-10-31 | 1.80 | 1.50 | +20.0% |
| 2024-07-26 | 2.07 | 1.63 | +27.4% |
| 2024-04-25 | -4.40 | -4.40 | -0.1% |
| 2024-02-02 | 1.70 | 1.58 | +7.8% |
| 2023-10-26 | 0.93 | 0.89 | +4.0% |
| 2023-07-27 | 1.75 | 1.99 | -12.0% |
| 2023-04-27 | 2.05 | 1.97 | +3.9% |
| 2023-02-02 | 1.82 | 1.73 | +5.2% |
| 2022-10-25 | 1.99 | 1.83 | +8.5% |
| 2022-07-27 | 1.93 | 1.80 | +7.3% |
| 2022-04-29 | 1.96 | 1.90 | +3.3% |
| 2022-02-04 | 1.83 | 1.80 | +1.7% |
| 2021-10-27 | 2.00 | 1.92 | +4.3% |
| 2021-07-28 | 1.93 | 1.90 | +1.8% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| BMY ★ | $111B | 15.3 | 8.8 | 2.3 | 7.8 | 5.5 | 72.0% | 2.6% | 9.2% | 8.86% |
| LLY | $949B | 37.7 | 23.9 | 13.1 | 27.3 | 30.5 | 82.8% | 55.5% | 169.9% | 0.96% |
| UNH | $343B | 28.5 | 18.1 | 0.8 | 18.5 | 3.5 | 18.8% | 2.0% | 0.7% | 5.15% |
| JNJ | $537B | 25.8 | 17.5 | 5.6 | 16.6 | 6.6 | 68.0% | 9.9% | -52.9% | 2.33% |
| MRK | $286B | 32.6 | 12.1 | 4.3 | 11.2 | 6.2 | 76.7% | 4.9% | — | 4.92% |
| ABBV | $381B | 105.1 | 13.3 | 6.1 | 14.8 | -57.2 | 72.0% | 12.4% | -46.2% | 5.47% |
| PFE | $146B | 19.5 | 9.0 | 2.3 | 7.8 | 1.6 | 74.8% | 5.4% | -10.1% | 8.50% |
| TMO | $179B | 26.5 | 17.7 | 4.0 | 19.4 | 3.4 | 40.9% | 6.2% | 11.3% | 3.08% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 36.69%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 171,682,888 | 8.41% |
| Vanguard Capital Management LLC | 132,320,240 | 6.48% |
| State Street Corporation | 98,564,914 | 4.83% |
| JPMORGAN CHASE & CO | 92,475,194 | 4.53% |
| Charles Schwab Investment Management | 61,115,373 | 2.99% |
| Geode Capital Management, LLC | 55,286,174 | 2.71% |
| Vanguard Portfolio Management LLC | 46,230,155 | 2.26% |
| Bank of America Corporation | 32,586,981 | 1.60% |
| AQR Capital Management, LLC | 29,631,105 | 1.45% |
| Morgan Stanley | 29,198,554 | 1.43% |
Insider activity · 90d
No insider trades for BMY in last 90d.
Analyst estimates
yfinanceConsensus: hold (mean 2.51724). Distribution requires FINNHUB_API_KEY.
SEC filings
No CIK found for BMY.
About
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In …